<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02771808</url>
  </required_header>
  <id_info>
    <org_study_id>14691</org_study_id>
    <nct_id>NCT02771808</nct_id>
  </id_info>
  <brief_title>Haptoglobin Polymorphism as a Determinant of Adverse Outcome After Cardiac Surgery in Diabetic Patients</brief_title>
  <official_title>Haptoglobin Polymorphism as a Determinant of Adverse Outcome After Cardiac Surgery in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Anesthesia Research Society (IARS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific aim 1a will test the hypothesis that diabetic patients with 2-2 haptoglobin genotype
      have higher indices of postoperative myocardial injury (creatine kinase MB isoenzyme ,
      Troponin I ) and renal injury (as indicated by elevated creatinine, cytostatin C and
      glomerular filtration rate). Of note, significantly elevated levels (&gt;5 times the upper
      normal limit) of creatine kinase MB isoenzyme and troponins postoperatively have been
      associated with postoperative myocardial ischemia/infarction and are a predictor of
      short-term and long-term mortality after cardiac surgery.

      Specific aim 1b will evaluate preoperative and postoperative indices of oxidative stress
      (such as isoprostane f2 alpha and malondialdehyde) and will evaluate whether patients with
      type 2-2 haptoglobin express increased oxidative stress. The investigators will also try to
      correlate whether patients with increased oxidative stress are those with elevated indices of
      myocardial and/or renal injury Specific aim 1c will try to evaluate whether patients with
      type 2-2 haptoglobin also have increased levels of inflammatory indices (C-reactive
      protein,[interleukin] IL-1, IL-2, IL-6, TNF[tumor necrosis factor]) and try to correlate the
      findings with postoperative myocardial and or renal injury.

      The incidence of atrial fibrillation after coronary artery bypass graft ranges from 19% to
      27%. The investigators will also look at any correlation of the type 2-2 haptoglobin and the
      incidence of post-operative atrial fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes mellitus is a major risk factor for postoperative morbidity and mortality after
      cardiac surgery, mainly because of accelerated atherosclerosis and target-organ injury that
      predispose these patients to increased incidence of postoperative morbidity (such as but not
      limited to, postoperative adverse cardiac events, renal injury or stroke) and mortality.

      Over the past several years haptoglobin has been identified as a risk factor that predicts
      the development of cardiovascular complications in diabetics. There are 3 major haplotypes of
      haptoglobin: 1-1; 1-2 and 2-2. Several studies have demonstrated that diabetic individuals
      with the 2-2 genotype have up to 5 fold increased risk to develop cardiovascular
      complications as compared to diabetic patients with a non-2-2 haptoglobin genotype. There is
      no data in the literature that evaluated whether the haptoglobin 2-2 genotype is a risk
      factor for increased postoperative morbidity and/or mortality after cardiac surgery in
      patients with DM.

      Therefore, the aims of the study are to evaluate whether diabetic patients with the 2-2
      genotype are at increased risk for postoperative morbidity and/or mortality after cardiac
      surgery.

      Preliminary studies in diabetic patients demonstrated that those with haptoglobin 2-2
      genotype are at increased risk for cardiovascular complications of diabetes. Moreover, these
      patients were found to have increased in-hospital mortality after acute MI compared to
      diabetic individuals that do not have the 2-2 genotype, and they also suffer from increased
      incidence of post catheterization stent thrombosis compared to diabetics that do not have the
      2-2 genotype
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of participants with myocardial injury</measure>
    <time_frame>24 hours post CPB</time_frame>
    <description>number of participants with general markers for myocardial injury</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of participants with renal injury</measure>
    <time_frame>24 hrs post CPB</time_frame>
    <description>number of participants with markers of kidney injury (cystatin C, creatinine, GFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with incidence of new onset atrial fibrillation</measure>
    <time_frame>day 15</time_frame>
    <description>incidence of new onset atrial fibrillation will be recorded</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">83</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>diabetic patients</arm_group_label>
    <description>obtain biomarker samples from diabetic patients and examine for 1-1 &amp; 1-2 &amp; 2-2 haptoglobin genotype</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biomarker samples</intervention_name>
    <description>biomarker samples for haptoglobin genotype (RT-PCR) and phenotype (hemoglobin electrophoresis) general markers for oxidative stress (isoprostane f2 alpha, malondialdehyde) markers of inflammation (CRP, IL-1, 2, 6, 10 and TNF) markers of cardiac injury (CPK, troponins and BNP) markers of kidney injury (cystatin C, creatinine, GFR)</description>
    <arm_group_label>diabetic patients</arm_group_label>
    <other_name>haptoglobin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult diabetic patients scheduled for an elective cardiac surgery on pump at UVA
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age and older

          -  Scheduled for an elective cardiac surgery on pump

          -  Diabetic -type I or type II

          -  Informed consent

        Exclusion Criteria:

          -  Patients with chronic hemolytic disorders;

          -  Patients with hemoglobinopathies

          -  Enrollment in another interventional clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Raphael, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UVA Anesthesiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol. 2004 Dec 21;44(12):2293-300. Review.</citation>
    <PMID>15607389</PMID>
  </reference>
  <reference>
    <citation>Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes and mortality following acute coronary syndromes. JAMA. 2007 Aug 15;298(7):765-75.</citation>
    <PMID>17699010</PMID>
  </reference>
  <reference>
    <citation>Bucerius J, Gummert JF, Walther T, Doll N, Falk V, Onnasch JF, Barten MJ, Mohr FW. Impact of diabetes mellitus on cardiac surgery outcome. Thorac Cardiovasc Surg. 2003 Feb;51(1):11-6. Erratum in: Thorac Cardiovasc Surg. 2003 Apr;51(2):113.</citation>
    <PMID>12587082</PMID>
  </reference>
  <reference>
    <citation>Carson JL, Scholz PM, Chen AY, Peterson ED, Gold J, Schneider SH. Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. J Am Coll Cardiol. 2002 Aug 7;40(3):418-23.</citation>
    <PMID>12142105</PMID>
  </reference>
  <reference>
    <citation>Thourani VH, Weintraub WS, Stein B, Gebhart SS, Craver JM, Jones EL, Guyton RA. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg. 1999 Apr;67(4):1045-52.</citation>
    <PMID>10320249</PMID>
  </reference>
  <reference>
    <citation>Levy AP, Hochberg I, Jablonski K, Resnick HE, Lee ET, Best L, Howard BV; Strong Heart Study. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Cardiol. 2002 Dec 4;40(11):1984-90.</citation>
    <PMID>12475459</PMID>
  </reference>
  <reference>
    <citation>Roguin A, Koch W, Kastrati A, Aronson D, Schomig A, Levy AP. Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care. 2003 Sep;26(9):2628-31.</citation>
    <PMID>12941730</PMID>
  </reference>
  <reference>
    <citation>Suleiman M, Aronson D, Asleh R, Kapeliovich MR, Roguin A, Meisel SR, Shochat M, Sulieman A, Reisner SA, Markiewicz W, Hammerman H, Lotan R, Levy NS, Levy AP. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes. 2005 Sep;54(9):2802-6.</citation>
    <PMID>16123372</PMID>
  </reference>
  <reference>
    <citation>Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res. 2005 Mar 4;96(4):435-41. Epub 2005 Jan 20.</citation>
    <PMID>15662028</PMID>
  </reference>
  <reference>
    <citation>Guetta J, Strauss M, Levy NS, Fahoum L, Levy AP. Haptoglobin genotype modulates the balance of Th1/Th2 cytokines produced by macrophages exposed to free hemoglobin. Atherosclerosis. 2007 Mar;191(1):48-53. Epub 2006 Jul 3.</citation>
    <PMID>16820150</PMID>
  </reference>
  <reference>
    <citation>Greenson N, Macoviak J, Krishnaswamy P, Morrisey R, James C, Clopton P, Fitzgerald R, Maisel AS. Usefulness of cardiac troponin I in patients undergoing open heart surgery. Am Heart J. 2001 Mar;141(3):447-55.</citation>
    <PMID>11231444</PMID>
  </reference>
  <reference>
    <citation>Muehlschlegel JD, Perry TE, Liu KY, Nascimben L, Fox AA, Collard CD, Avery EG, Aranki SF, D'Ambra MN, Shernan SK, Body SC; CABG Genomics Investigators. Troponin is superior to electrocardiogram and creatinine kinase MB for predicting clinically significant myocardial injury after coronary artery bypass grafting. Eur Heart J. 2009 Jul;30(13):1574-83. doi: 10.1093/eurheartj/ehp134. Epub 2009 Apr 30.</citation>
    <PMID>19406870</PMID>
  </reference>
  <reference>
    <citation>Paparella D, Cappabianca G, Visicchio G, Galeone A, Marzovillo A, Gallo N, Memmola C, Schinosa Lde L. Cardiac troponin I release after coronary artery bypass grafting operation: effects on operative and midterm survival. Ann Thorac Surg. 2005 Nov;80(5):1758-64.</citation>
    <PMID>16242452</PMID>
  </reference>
  <reference>
    <citation>Ramsay J, Shernan S, Fitch J, Finnegan P, Todaro T, Filloon T, Nussmeier NA. Increased creatine kinase MB level predicts postoperative mortality after cardiac surgery independent of new Q waves. J Thorac Cardiovasc Surg. 2005 Feb;129(2):300-6.</citation>
    <PMID>15678039</PMID>
  </reference>
  <reference>
    <citation>Adabag AS, Rector T, Mithani S, Harmala J, Ward HB, Kelly RF, Nguyen JT, McFalls EO, Bloomfield HE. Prognostic significance of elevated cardiac troponin I after heart surgery. Ann Thorac Surg. 2007 May;83(5):1744-50.</citation>
    <PMID>17462392</PMID>
  </reference>
  <reference>
    <citation>Fox AA, Shernan SK, Collard CD, Liu KY, Aranki SF, DeSantis SM, Jarolim P, Body SC. Preoperative B-type natriuretic peptide is as independent predictor of ventricular dysfunction and mortality after primary coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2008 Aug;136(2):452-61. doi: 10.1016/j.jtcvs.2007.12.036.</citation>
    <PMID>18692657</PMID>
  </reference>
  <reference>
    <citation>Cuthbertson BH, Croal BL, Rae D, Gibson PH, McNeilly JD, Jeffrey RR, Smith WC, Prescott GJ, Buchan KG, El-Shafei H, Gibson GA, Hillis GS. N-terminal pro-B-type natriuretic peptide levels and early outcome after cardiac surgery: a prospective cohort study. Br J Anaesth. 2009 Nov;103(5):647-53. doi: 10.1093/bja/aep234. Epub 2009 Aug 27.</citation>
    <PMID>19713279</PMID>
  </reference>
  <reference>
    <citation>Bahar I, Akgul A, Ozatik MA, Vural KM, Demirbag AE, Boran M, Tasdemir O. Acute renal failure following open heart surgery: risk factors and prognosis. Perfusion. 2005 Oct;20(6):317-22.</citation>
    <PMID>16363316</PMID>
  </reference>
  <reference>
    <citation>Brown JR, Cochran RP, Leavitt BJ, Dacey LJ, Ross CS, MacKenzie TA, Kunzelman KS, Kramer RS, Hernandez F Jr, Helm RE, Westbrook BM, Dunton RF, Malenka DJ, O'Connor GT; Northern New England Cardiovascular Disease Study Group. Multivariable prediction of renal insufficiency developing after cardiac surgery. Circulation. 2007 Sep 11;116(11 Suppl):I139-43.</citation>
    <PMID>17846294</PMID>
  </reference>
  <reference>
    <citation>McGuinness J, Bouchier-Hayes D, Redmond JM. Understanding the inflammatory response to cardiac surgery. Surgeon. 2008 Jun;6(3):162-71. Review.</citation>
    <PMID>18581753</PMID>
  </reference>
  <reference>
    <citation>Warren OJ, Smith AJ, Alexiou C, Rogers PL, Jawad N, Vincent C, Darzi AW, Athanasiou T. The inflammatory response to cardiopulmonary bypass: part 1--mechanisms of pathogenesis. J Cardiothorac Vasc Anesth. 2009 Apr;23(2):223-31. doi: 10.1053/j.jvca.2008.08.007. Epub 2008 Oct 19. Review.</citation>
    <PMID>18930659</PMID>
  </reference>
  <reference>
    <citation>Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg. 2002 Feb;21(2):232-44. Review.</citation>
    <PMID>11825729</PMID>
  </reference>
  <reference>
    <citation>Orhan G, Yapici N, Yuksel M, Sargin M, Senay S, Yalçin AS, Aykaç Z, Aka SA. Effects of N-acetylcysteine on myocardial ischemia-reperfusion injury in bypass surgery. Heart Vessels. 2006 Jan;21(1):42-7.</citation>
    <PMID>16440148</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2010</study_first_submitted>
  <study_first_submitted_qc>May 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Jacob Raphael</investigator_full_name>
    <investigator_title>Associate Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>CABG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

